ClinEvident™ · by Scientari
Clinical evidence for healthspan.
Not marketing claims.
Independent six-dimension grading of how strong the evidence really is that an intervention extends healthspan — across cardiology, metabolic, inflammation, renal, and longevity. Every grade links to published research. No affiliate bias. No hype.
The Rx–Supplement Evidence Divide
No supplement in our registry scores above C+. The highest-evidence healthspan interventions are repurposed prescription drugs. This isn't bias — it's what the published data shows.
Empagliflozin (SGLT2i)
A+SGLT2 inhibitors (empagliflozin, dapagliflozin) are the highest-evidence longevity compound class in the registry, with A+ grades for both…
Semaglutide
A+Semaglutide is the highest-evidence longevity compound in the ClinEvident registry. Originally approved for type 2 diabetes (Ozempic) and…
Metformin
B-Metformin has extensive observational evidence suggesting longevity benefits, including the landmark UKPDS study showing reduced all-cause…
Urolithin A (Mitopure)
C+Urolithin A is the cleanest evidence story in the supplement space. Timeline/Amazentis has published six human clinical trials showing…
CoQ10 (Ubiquinol)
C+CoQ10 has the longest clinical evidence history of any longevity supplement. A 2024 meta-analysis found CoQ10 supplementation significantly…
Rapamycin (Sirolimus)
CRapamycin has the strongest preclinical lifespan extension data of any compound — consistent results across yeast, worms, flies, and…
Spermidine
C-Spermidine is an autophagy inducer with an interesting epidemiological signal — the Bruneck Study (n=829, 20-year follow-up) found that…
NR (Nicotinamide Riboside / Tru Niagen)
C-NR (Tru Niagen by ChromaDex) shares the NAD+ precursor mechanism with NMN but has a slightly stronger evidence base. ChromaDex has…
NMN (Nicotinamide Mononucleotide)
C-NMN is among the most popular longevity supplements, but its evidence grade is D+ — reflecting a significant gap between consumer…
D+Q (Dasatinib + Quercetin) Senolytic
D+D+Q is the original senolytic combination, pioneered by James Kirkland at Mayo Clinic. The concept — selectively killing senescent cells…
Fisetin
D+Fisetin exemplifies the senolytic evidence gap. A 2018 preclinical study identified it as the most potent senolytic flavonoid, extending…
Quercetin (standalone)
D+Quercetin as a standalone supplement has weak evidence for longevity. Its primary interest is as the 'Q' in D+Q senolytic therapy, but…
How We Grade Evidence
Every intervention is scored across six dimensions of the Evidence Grading Framework (EGF), published as the ClinEvident Evidence Grading Standard. The methodology is published. The grades are transparent. The data speaks.
Human Outcome Weight
Does it change hard clinical endpoints in humans? RCTs with mortality, morbidity, or functional outcomes score highest.
30%Biomarker Relevance
Are the biomarkers it moves actually predictive of aging or disease? Validated surrogate endpoints vs. exploratory markers.
20%Signal Source Quality
Where does the evidence come from? Peer-reviewed RCTs in NEJM vs. open-label pilot studies vs. press releases.
15%Organ Specificity
How precisely does the evidence map to specific organ systems? Targeted organ data vs. whole-organism generalities.
15%Interaction Certainty
How well-characterized are the interactions with other compounds? Graded at the compound-pair level.
SeparateTranslational Maturity
How close is the evidence to clinical actionability? Phase 3 complete vs. animal-only vs. in-vitro.
20%Cut through the noise.
Free accounts see compound overviews and grades. Subscribers get full clinical detail, dose-signal data, regulatory intelligence, and unlimited interaction checks.